Afatinib as a novel potential treatment option for NRG1 fusion-positive tumors.

Janessa Laskin,Jacques Cadranel,Daniel J. Renouf,Benjamin A. Weinberg,Yasushi Goto,Michaël Duruisseaux,Khaled A. Tolba,Eva Brandén,Robert C. Doebele,Christoph Heining,Richard F. Schlenk,Parneet K. Cheema,Martin R. Jones,Domenico Trombetta,Lucia Anna Muscarella,A. Cseh,Flavio Solca,Stephen V. Liu

Afatinib as a novel potential treatment option for NRG1 fusion-positive tumors.

2019

Janessa Laskin
Jacques Cadranel
Daniel J. Renouf
Benjamin A. Weinberg
Yasushi Goto
Michaël Duruisseaux
Khaled A. Tolba
Eva Brandén
Robert C. Doebele
Christoph Heining
Richard F. Schlenk
Parneet K. Cheema
Martin R. Jones
Domenico Trombetta
Lucia Anna Muscarella
A. Cseh
Flavio Solca
Stephen V. Liu

110Background: Neuregulin 1 (NRG1) is a growth factor that binds HER3/4 and activates ErbB signalling pathways. NRG1 gene fusions function as oncogenic drivers and represent a potential therapeutic...

Keywords:

Neuregulin 1
Afatinib
Growth factor
Signalling
Cancer research
Biology
Gene
ErbB
signalling pathways
treatment options

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations